Introduction
The optimal timing of renal replacement therapy (RRT) initiation in critically ill patients with acute kidney injury (AKI) is a longstanding clinical dilemma. Among patients experiencing life-threatening complications associated with AKI, such as marked hyperkalemia, metabolic acidosis, and major volume overload, the decision to promptly initiate RRT is unequivocal. 1 However, for critically ill patients with severe AKI but without an emergent indication for RRT initiation, the appropriate triggers to initiate RRT are unclear. The lack of definitive evidence has spawned two broad philosophies of care: an early or preemptive approach to initiation of RRT versus a strategy of watchful waiting, wherein RRT is deferred until confronted with life-threatening complications of AKI.
There are plausible benefits underlying a preemptive strategy for RRT initiation in critically ill patients with AKI. Earlier RRT initiation can facilitate reliable extracorporeal ultrafiltration and proactively counter the fluid accumulation frequently observed in critically ill patients with AKI. Similarly, earlier RRT initiation may promote clinical recovery through the removal of solutes that putatively mediate the toxicity of AKI. RRT-delivered solute clearance mediated by diffusion, convection, and membrane adsorption may mitigate the inflammatory milieu that is frequently observed in AKI, though the precise mechanisms remain unclear. RRT is an effective means of countering the metabolic acidosis that accompanies AKI thereby preventing the downstream hemodynamic consequences of acidemia. The benefits of preemptive RRT are supported by observational data 2,3 and a recently published single-center randomized controlled trial (RCT). 4 Notwithstanding these potential advantages, the uncritical adoption of preemptive RRT into clinical practice based on the current evidence base would be premature. The provision of RRT and the dedicated central venous access for RRT both carry the risk of complications. Although difficult to predict, some patients with severe AKI may survive and recover kidney function without having received RRT. As a result, a routine strategy of preemptive RRT might expose some critically ill patients, perhaps unnecessarily, to greater risk relative to benefit while using greater resources. Moreover, two recent multicenter RCTs did not show clinical benefit with earlier initiation. 5, 6 The effect of the timing of RRT initiation on clinical outcomes has been identified as a top priority for research in the fields of nephrology and critical care. 7 The Kidney Disease Improving Global Outcomes clinical practice guidelines for AKI recognized the uncertainty in this area and recommended a definitive trial. 8 The National Institute for Health and Care Excellence in the United Kingdom also explicitly called for a trial that would randomize patients with severe AKI and no urgent indications to immediate or deferred initiation of RRT. 9 Recently completed trials in this area were likely underpowered to detect a realistic treatment effect favoring any RRT initiation strategy and were all limited to one country. [4] [5] [6] Moreover, these trials predicated enrollment on the achievement of guideline-defined criteria for AKI without considering whether eligible patients would be conceivable candidates for RRT in the context of usual care. Accordingly, we aimed to conduct a pragmatic RCT to definitively answer whether, in critically ill patients with severe AKI, accelerated RRT initiation confers a reduction in allcause mortality as compared to a standard strategy, whereby RRT is initiated if urgent complications of AKI arise or based on clinician judgment.
Preparatory Work
The ongoing STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial represents the culmination of a research program comprising observational studies describing prevailing clinical practice, 10,11 a Canada-wide practice survey, 12 and a systematic review of studies comparing earlier versus delayed strategies of RRT initiation in critically ill patients with AKI. 13 We also completed a pilot RCT that confirmed the feasibility of patient recruitment, implementation of the protocol, and participant follow up. 14, 15 The experiences learned while conducting the pilot RCT informed protocol modifications in the main phase of the study as reported herein.
We describe the STARRT-AKI protocol according to the guidelines set out in the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Statement. 16 
Methods

Trial Design
STARRT-AKI is a multi-national pragmatic open-label RCT of critically ill patients with severe AKI comparing a preemptive strategy (accelerated arm) versus a strategy of watchful waiting and RRT initiation guided by AKI-related complications and clinician judgment (standard arm). The protocol was finalized on October 5, 2015, and remains in effect without intervening amendments.
Trial Oversight
The trial is approved by the Research Ethics Boards at the University of Alberta (file number: Pro00063318), St. Michael's Hospital (file number: 16-009), and the affiliated institutional research boards of all participating sites. The trial is governed by an international steering committee (Supplementary Material Appendix 1).
The trial is registered at ClinicalTrials.gov (NCT02568722; October 6, 2015).
Population and Eligibility
The STARRT-AKI eligibility criteria are shown in Table 1 . After meeting all the inclusion criteria and elimination of the first 8 exclusions, a patient would be considered provisionally eligible. Achievement of full eligibility requires confirmation of equipoise by the attending clinicians (intensivist as well as the nephrologist at centers where nephrologists manage RRT orders) caring for the patient. Equipoise will be determined when attending clinicians agree that there is neither an urgent reason to immediately commence RRT (exclusion 9) nor is it mandated to defer RRT (exclusion 10). Once a patient is found to be fully eligible (ie, all inclusion criteria met and no exclusion criteria applicable), there is a 12-hour window, during which consent must be obtained (or deferred/ waived consent invoked, as approved by local research ethics boards). If consent cannot be secured during this time window, the patient can no longer be considered for participation in the trial. The screening process is depicted in Figure  1 . A flow diagram will be reported according to the Consolidated Standards of Reporting Trials (CONSORT) recommendations for reporting randomized trials.
Randomization
Participants will be randomized 1:1 to accelerated versus standard initiation of RRT with variable block sizes and stratified by center using a centralized concealed web-based randomization system that is managed at the Applied Health Research Center (AHRC) at St. Michael's Hospital in Toronto (http:// www.stmichaelshospital.com/research/ahrc/index.php).
Interventions
Accelerated RRT Initiation
Participants allocated to the accelerated RRT initiation strategy will initiate RRT within 12 hours of reaching full eligibility. This 12-hour window includes the time required to obtain consent (as described above), place a dialysis catheter, and initiate RRT.
Standard RRT Initiation
Clinicians caring for participants allocated to the standard arm of the trial will be discouraged from commencing RRT unless the following conditions are met: (1) persistent AKI, defined as a serum creatinine that remains >50% of the value recorded at randomization; and 2) one or more of the following indications for RRT initiation: (i) serum potassium ≥6.0 mmol/L; or (ii) pH ≤7.20 or serum bicarbonate ≤12 mmol/L; or (iii) evidence of severe respiratory failure, based on a PaO 2 /FiO 2 ≤200 and clinical perception of volume overload; or (iv) persistent AKI for ≥72 hours from randomization. RRT may still be commenced in participants allocated to the standard RRT initiation strategy at any time based on the judgment of the attending clinician(s). In circumstances where RRT is commenced in the absence of meeting the trial-specified criteria, the clinician will be asked to specify the primary reason for initiating RRT. There is no obligation to initiate RRT in the standard arm, even among participants who fulfill one of the aforementioned conditions. For example, if a patient in the standard arm has a serum potassium concentration of 6.3 mmol/L, Table 1 . Eligibility Criteria for Enrollment in the STARRT-AKI Trial.
The following inclusion criteria have been established, all of which must be fulfilled: 1. Age ≥18 years, and 2. Admission to a critical care unit, defined as any unit capable of providing invasive mechanical ventilation, and 3. Evidence of kidney dysfunction, defined as a serum creatinine ≥100 μmol/L in women and ≥130 μmol/L in men that has not declined by ≥27 μmol/L compared to the highest value recorded in the preceding 48 hours, and 4. Evidence of severe AKI based on at least 1 of the following 3 criteria:
a. ≥2-fold increase in serum creatinine from baseline, or b. serum creatinine ≥354 μmol/L, accompanied by evidence of a minimum increase of 27 μmol/L from the baseline serum creatinine, or c. urine output <6 mL/kg in preceding 12 hours The presence of 1 or more of the following exclusion criteria disqualifies a participant from participation: 1. Serum potassium concentration >5.5 mmol/L, based on last available bloodwork 2. Serum bicarbonate concentration <15 mmol/L, based on last available bloodwork 3. Presence of a drug overdose that necessitates initiation of RRT 4. Lack of commitment to provide RRT due to limitations on the escalation of life support measures 5. Any RRT within the previous 2 months 6. Kidney transplant within the past 365 days 7. Known pre-hospitalization advanced chronic kidney disease, defined by an estimated glomerular filtration rate <20 mL/min/1.73 m 2 , as measured by the Chronic Kidney Disease Epidemiology Collaboration equation, using an outpatient serum creatinine value obtained within 365 days of admission for the current hospitalization 8. Presence or strong clinical suspicion of renal obstruction, rapidly progressive glomerulonephritis, vasculitis, thrombotic microangiopathy (eg, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, malignant hypertension, scleroderma renal crisis) or acute interstitial nephritis If the patient fulfills all inclusion criteria and no exclusion criteria have been identified the patient is deemed to be provisionally eligible. The next step is to ascertain whether the most responsible clinician(s) (the attending critical care physician and where relevant, the attending nephrologist) are in a position of clinical equipoise with respect to the 2 RRT initiation strategies that the provisionally eligible patient may receive if he/she is randomized. This is performed in practice by ascertaining the presence of the following 2 exclusion criteria: 9. Clinician(s) caring for patient believe(s) that immediate RRT is absolutely mandated 10. Clinician(s) caring for patient believe(s) that deferral of RRT initiation is mandated A negative answer by all of the relevant clinicians to exclusions 9 and 10 formally transitions the patient's status from provisional to full eligibility. The time of full eligibility is noted and marks the beginning of a 12-hour period, during which informed consent must be obtained (or alternate consent approaches invoked) and the participant randomized. If consent cannot be secured during the 12 hours after full eligibility is established, the patient is no longer eligible for participation.
Note. STARRT-AKI = STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury; RRT = renal replacement therapy.
the clinician may opt to use medical interventions to promote potassium excretion and is not obligated to commence RRT. Among participants allocated to the standard strategy, most are expected to commence RRT; however, we anticipate that a significant proportion will not receive RRT due to either kidney recovery or death, as demonstrated in our pilot trial. 14 
RRT Delivery in the STARRT-AKI Trial
The decision regarding RRT modality will be made by the attending physician(s). RRT will be delivered using a set of recommended guidelines aligned with contemporary clinical practice, as described in the operations manual (Supplementary Material Appendix 2). 
Criteria for Discontinuation of RRT
Once started in either treatment arm, RRT will continue until one of the following is encountered: (1) death; or (2) withdrawal of life-support interventions in the context of a change in the patient's goals of care; or (3) kidney function recovery with no need for continued RRT as per the clinician's judgment. If kidney function is deemed to be inadequate after a period of RRT discontinuation, RRT may be reinitiated at the discretion of the treating clinician.
Frequency and Duration of Follow-Up
Each participant is followed for a minimum of 90 days after randomization ( Figure 2 ). In jurisdictions where this is feasible, follow up from day 91 to 365 will occur using linkages to administrative data.
We will monitor and collect data on all RRT that is administered during the first 14 days after randomization, as well as safety events that arise during this time period. As per recommendations for the follow up of patients surviving an episode of AKI, all participants who are alive and independent of RRT at 90 days following randomization will be asked to submit a blood sample for creatinine measurement (and estimation of glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaborative equation) and a spot urine sample for assessment of the urine albumin:creatinine ratio. 8
Outcomes
Primary Outcome
The primary outcome is all-cause mortality within 90 days of randomization.
Secondary Outcomes
The secondary outcomes are: 
Safety and Adverse Events
All adverse events deemed to be related to one of the study interventions are being ascertained and recorded for the first 14 days after randomization. Specifically, events that are conceivably related to the insertion of a dialysis catheter, administration of RRT, or occurring as a complication of delaying RRT will be captured ( Table 2) . A serious adverse event (SAE) includes any adverse event that meets at least 1 of the following conditions:
1. Is fatal 2. Is perceived to be life threatening 3. Requires in-patient hospitalization or prolongation of an existing hospitalization 4. Results in significant disability or incapacity For this study, a reportable SAE must meet the definition noted above and also be considered:
1. An atypical event, defined as clinically significant and unexpected in the context of critical illness complicated by AKI; AND 2. An event that is at least possibly related to the study procedures.
Power and Sample Size
We anticipate a 90-day mortality rate of 40% in the standard arm. This mortality rate is compatible with 90-day mortality reported in contemporaneous cohorts of critically ill patients with severe AKI treated with RRT. 19, 20 There is no clear guidance on the estimated risk reduction afforded by accelerated RRT. We selected a relative risk reduction of 15% (absolute risk reduction 6%) as a plausible magnitude of effect that is clinically important. With a Type I error of 0.05 and power of 0.90, a sample size of 1359 participants/arm would be required (total 2718). In order to account for the interim analyses, the required sample size was increased to 2780. After estimating a combined rate of crossover and dropouts of 3% (as derived from the pilot phase), 14 our target recruitment is at least 2866 participants.
Data Management
All data will be reviewed by dedicated managers at The George Institute in Sydney, Australia (for participants enrolled in Australia and China), the Medical Research Institute of New Zealand (for patients enrolled in New Zealand) and the Applied Health Research Centre in Toronto, Canada (for participants enrolled in all other countries). Managers will issue queries to participating centers regarding suspected data errors which will then require clarification before being considered resolved. Source data will be reviewed for randomly selected participants through on-site monitoring or submission of de-identified documentation.
Statistical Analyses
A detailed statistical analysis plan and proposed presentation of data will be published separately prior to completion of planned recruitment. In brief, the primary outcome of 90-day mortality will be evaluated using an intention-totreat approach. A simple comparison of proportions will be performed using a chi-squared test. The risk ratio and risk difference will be estimated with 95% confidence intervals. RRT dependence at 90 days is the most important secondary outcome and requires a more nuanced approach, as the noninclusion of participants who died might obviate the intergroup balance afforded by randomization. We will consider 2 complementary approaches to examine this question. First, we will develop a model for the primary outcome to estimate the probabilities of 90-day survival. We will then use the reciprocals of these probabilities as weights in a logistic regression for RRT dependence, resulting in an inverse probability weighted analysis. The second approach will employ a multinomial regression model to jointly consider the following states: dead at 90 days, alive at 90 days receiving RRT, and alive at 90 days and RRT-free. A similar approach will be used to estimate the patient's status at 365 days. In addition, time-to-event models that incorporate competing risks or multiple outcomes may be considered.
Duration of ventilation, vasoactive therapy, intensive care unit (ICU) stay and hospitalization, and albuminuria at 90 days (expressed as the urinary albumin to creatinine ratio in mg/mmol) will be compared by means or medians using a t-test or Mann-Whitney U test, respectively, as appropriate. Finally, RRT dependence at 90 days, a composite of death or RRT dependence at 90 days, major adverse kidney events at 90 days (MAKE 90 ), eGFR decline to <75% of baseline eGFR, death at all pre-specified time milestones, ICU readmission and rehospitalization within 90 days will be compared using chi-squared tests, respectively. Where appropriate, the inverse probability weighted approach will be used to ensure that "survivor-only" analyses are not misleading.
Interim analyses for efficacy based on the primary outcome will be performed when 25, 50, and 75% of participants have completed 90-day follow-up. Given the risk of false-positive results with early stopping for benefit, statistical significance will be declared using extreme P-values established by O'Brien-Fleming boundaries on the primary outcome (90-day mortality). 21
Planned Subgroup Analyses
We will evaluate the effect of accelerated versus standard RRT on the primary outcome of 90-day mortality in the following a priori defined subgroups:
• • Patient sex (since sex may affect muscle mass which in turn affects serum creatinine, severity of AKI may be differentially perceived in men and women)
• • The presence of preexisting chronic kidney disease (based on the plausible modifying effect of preexisting chronic kidney disease on mortality and progression to long-term RRT dependence) • • Baseline Simplified Acute Physiology Score (SAPS) II score (based on the possibility that the timing of RRT initiation may have a minimal impact on modifying mortality in patients with a low SAPS score who have a favorable prognosis as well as in individuals with a high SAPS score who have a poor prognosis) • • Surgical (versus medical) status (based on the rationale that a recently completed trial that demonstrated lower mortality in patients who received earlier RRT initiation was conducted in a predominantly postsurgical population) 4 • • Patients with sepsis and septic shock, as defined by the Sepsis-3 criteria 22 (based on the rationale that earlier RRT, due to more aggressive removal of inflammatory Blood in the pleural space following dialysis catheter insertion Bleeding
Bleeding described by clinician inserting dialysis catheter requiring transfusion of ≥1 unit(s) of packed red blood cells and/or surgical intervention/repair within 12 hours following insertion Thrombus
An ultrasound-confirmed occlusive or nonocclusive thrombus in the vein in which a dialysis catheter was placed (or remains in place) or in the venous system drained by the vein in which a dialysis catheter was placed Arterial puncture
As document by the clinician placing the catheter Bloodstream infection Infection in 2 blood culture sets (one drawn from dialysis catheter and the other from another site) with no proven alternative source for bloodstream infection as per ICU attending OR culture-positive recovery of the same organism from the dialysis catheter upon removal Air embolism
As documented in the medical chart Other Any other adverse event felt to be related to the patient's participation in the trial including any event felt to be the consequence of the patient's nonreceipt of RRT Note. RRT = renal replacement therapy.
mediators, might have a more prominent effect among patients with sepsis-associated AKI) • • Geographic regions of the world: North America; France; United Kingdom; Europe (not including France or the United Kingdom); Australia/New Zealand; Asia and South America (based on rationale that regional RRT and/or critical care practices may modify the relationship between the timing of RRT initiation and the outcomes of interest)
Health Economic Evaluation
A cost-utility analysis will be performed comparing the two approaches to RRT initiation in critically ill patients with AKI. This will be part of a broader health economic evaluation to be reported after the publication of the main trial findings.
Co-Enrollment
Patients recruited to STARRT-AKI may be considered for co-enrollment in observational studies or clinical trials, provided those studies do not modify the STARRT-AKI interventions or have a plausible interaction with the timing of RRT initiation. Investigators and coordinators will routinely review trials that are concurrently operating in ICUs at participating centers. After reviewing the trial protocol, the coprincipal investigators (R.W. or S.M.B.) will determine whether a trial is appropriate for co-enrollment.
Plasma-Lyte148 versUs Saline Study
The Plasma-Lyte148 versUs Saline Study (PLUS, ClinicalTrials.gov NCT02721654) recently commenced enrollment in Australia and New Zealand and is concurrently recruiting at several sites at which STARRT-AKI is active. 23 PLUS is evaluating the effect of resuscitation with Plasma-Lyte148 compared with 0.9% saline on the primary outcome of 90-day mortality in 8800 critically ill patients.
Since enrollment in PLUS occurs shortly following arrival in the ICU, recruitment into PLUS will generally take place before eligibility for STARRT-AKI is ascertained. Given the hypothesis that the PLUS intervention strategy may impact upon the risk of AKI progression and the initiation of RRT, efforts have been made to ensure that PLUS participants who enter STARRT-AKI are balanced across both RRT initiation strategies depending on the PLUS treatment allocation. At centers that are participating in PLUS, randomization into STARRT-AKI will be further stratified according to nonparticipation in PLUS, receipt of PLUS-Plasma-Lyte148, and receipt of PLUS-0.9% saline. For participants who are enrolled in PLUS, the PLUS study bag number (which is linked to the blinded PLUS study intervention) will be entered into the STARRT-AKI database. There will be no specific reporting on the subgroup of STARRT-AKI participants co-enrolled in the PLUS trial.
Limitations
Embedding the attending clinicians' declaration of equipoise into the eligibility criteria may create heterogeneity in the patients included within and across participating sites. We have not specifically protocolized any aspect of RRT delivery or critical care practice. There will be inevitable practice variability which should be balanced by randomization. However, the permitted flexibility in clinical practice in the context of an open-label design could introduce bias through the delivery of unbalanced cointerventions.
Trial Management
Coordination
The international coordinating and data management center is the Applied Health Research Center located at the Li Ka Shing Knowledge Institute (www.ahrconline.com) of St. Michael's Hospital in Toronto, Canada. Coordination for sites in Australia and China is managed by The George Institute, Sydney, Australia. Coordination for sites in New Zealand is managed by the Medical Research Institute of New Zealand, Wellington, New Zealand.
Steering Committee
The Steering Committee has assumed overall responsibility for conduct of the trial worldwide (Supplementary Material Appendix 1). The committee is chaired by the co-principal investigators (R.W. and S.M.B.) and meets monthly via teleconference to review recruitment progress, protocol adherence, protocol violations, and overall trial operations and logistics. A current list of investigators, personnel, and sites can be found in the Supplementary Material Appendix 3.
Data Safety and Monitoring Board
An independent data safety and monitoring board (DSMB) comprised of experts in clinical trials, biostatistics, critical care, and nephrology have been appointed to monitor the trial. DSMB membership and the charter guiding DSMB operations are found in Supplementary Material Appendix 4. The DSMB meets to review safety data following the enrollment of every 300 patients, to review the results of interim analyses, and on an ad hoc basis as indicated. The DSMB chair will communicate with the co-principal investigators after each meeting and provide recommendations regarding continuation of the trial. The DSMB may request evaluation of available trial data at any time at its discretion.
Implications
STARRT-AKI will provide high-quality evidence to answer one of the most vexing questions in the area of critical care nephrology. The trial is appropriately powered to assess a potential benefit of accelerated RRT initiation that is both plausible and clinically meaningful. The eligibility criteria reflect patients experiencing AKI for whom the question of when to initiate RRT is relevant. Pragmatic deployment of the interventions and the multinational nature of the trial will ensure that the findings are widely applicable.
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